Quick-Med Technologies, Inc. (QMDT) Research

Quick-Med Technologies, Inc. (QMDT) is a life sciences company focused on developing and bringing to market proprietary, broad-based technologies within the medical and consumer healthcare sectors. Its primary focus is on the research and development of biomedical products and devices, particularly those designed for antibacterial applications. The company's core technological innovations include: NIMBUS (Novel Intrinsically Micro-Bonded Utility Substrate): An advanced polymer family featuring antimicrobial, hemostatic (blood-clotting), and other beneficial properties suitable for a wide range of applications. Stay Fresh: A durable chemical formulation for textiles, serving as an effective antimicrobial agent against various bacteria. MultiStat: Patented methods and compounds developed for advanced skin therapy applications. QMDT serves a diverse clientele, including government agencies, healthcare and medical companies, apparel and textile manufacturers, and personal care product firms. Established in 1997, the company is headquartered in Gainesville, Florida.

Market snapshot

Symbol
QMDT
Price
$0.00
Day change
0.00%
Market cap
$29.9K
P/E ratio
-0.04x
52-week range
0.0001-0.0008
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • CanaQuest Medical Corp. (CANQF)
  • Ventura Cannabis & Wellness Corporation (CVHIF)
  • Deltagen Inc. (DGEN)
  • Emergent Health Corp (EMGE)
  • Net Medical Xpress Solutions, Inc. (NMXS)
  • NxGen Brands Inc. (NXGB)
  • Anbc, Inc. (SYUP)
  • THC Therapeutics, Inc. (THCT)

Recent insider activity

  • PHRONESIS PARTNERS L P — S-Sale (0 shares) on 2013-02-07
  • PHRONESIS PARTNERS L P — S-Sale (10100 shares) on 2013-02-07
  • PHRONESIS PARTNERS L P — S-Sale (25000 shares) on 2013-02-07
  • PHRONESIS PARTNERS L P — S-Sale (0 shares) on 2013-02-07
  • PHRONESIS PARTNERS L P — S-Sale (0 shares) on 2013-01-30

Open Quick-Med Technologies, Inc. (QMDT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.